Peptide and protein PEGylation: a review of problems and solutions.

By F. Veronese. Biomaterials, 2001

970 citations recorded by the source corpus.

Subfields: Biotechnology, Cancer Research, Materials Chemistry

View Paper: https://www.semanticscholar.org/paper/e2f0b347d29c135cec93799c1c6950c9c383054e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biotechnology

1. Reisa A. Sperling
2. Wolfgang J. Parak
3. C. Fee
4. J. V. Alstine

In Cancer Research

1. Reisa A. Sperling
2. Wolfgang J. Parak
3. D. Richardson
4. C. Fee
5. D. Kalinowski
6. J. V. Alstine

In Materials Chemistry

1. Reisa A. Sperling
2. Wolfgang J. Parak
3. C. Fee
4. J. V. Alstine

Citations in the corpus

• Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles (2010, background): “The same applies for molecules or particles: PEG-modified proteins (Veronese 2001) or drugs show increased water solubility and decreased immunogenicity in organisms, antibodies bind to a much lesser extent to the drug or protein, resulting e.g. in an increased half-life in the blood stream.”
• Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come (2016, background): “These investigators conjugated PEG to proteins (Abuchowski et al., 1977) and later demonstrated that PEGylation helped reduce the immunogenicity of therapeutics aswell as improve their safety and efficacy (Veronese, 2001; Veronese and Pasut, 2005).”
• PEG-proteins: Reaction engineering and separation issues (2006, background): “…for identifying PEGylated proteins from their elution profiles (Christakopoulos et al., 1998; Fortier and Laliberte, 1993; McGoff et al., 1988; Veronese, 2001) SEC columns calibrated in terms of molecular size rather than molecular weight give consistent results for protein and PEG standards…”